Overview

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

This is a single-center, randomized, open-label, single-dose, parallel-group study which will enroll and randomize approximately 48 subjects (to achieve 36 completers) with opioid use disorder (OUD) who are seeking treatment for OUD. The study includes both a Residential (Inpatient) and Non-Residential (Outpatient) Period.

Phase:

Phase 1

Details

Lead Sponsor:

Indivior Inc.

Treatments:

Analgesics, Opioid
Buprenorphine
Buprenorphine, Naloxone Drug Combination
Naloxone